Nemonoxacin Quinolone antibiotic

Although fluoroquinolones have been used over the lost few decades to successfully treat multiple bacterial infections, there is a need for new compounds that while taking advantage of the antimicrobial properties of the quinolone nucleus, show greater potency against, drug resistant bacteria, reduced drug-drug interactions and Improved patient tolerability Nemonoxacin (TC-873870) is a nonflourinated quinolone antibiotic with remarkable in vitro activity against a wide variety of clinically relevant pathogens, including methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae in several murine pulmonary infection models, the efficacy of nemonoxocin was greater than most of the currently available fluoroquinolones Studies in laboratory animals have ruled out the possibility of nemonozacin, inducing significant reproductive, cardiovascular allergic or phototoxic adverse events In addition, this novel quinolone has a good pharmacokinetic profile and is well tolerated Nemonoxacin is Currently undergoing phase II evaluation for the oral treatment of drug-sensitive and -resistant bacterial infections